The new administration's Labor Department clarified its stance on diversity initiatives based on existing employment law.
The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.
An updated guideline has been published by the AHA, ACC, and other organizations regarding the management of acute coronary syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback